Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life ‘LIver Network Activity’ (LINA) cohort update results

References

• Welzel TM, Asselah T, Dumas EO, et al. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. Lancet Gastroenterol Hepatol. 2017;2(7):494–500.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–1765.
   PubMed Web of Science ®Google Scholar
• Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs. 2014;23(9):1211–1223.
   PubMed Web of Science ®Google Scholar
• Poordad F, Shiffman ML, Ghesquiere W, et al. Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C). Antivir Ther. 2019;24(1):35–44.
   PubMed Web of Science ®Google Scholar
• Luetkemeyer AF, McDonald C, Ramgopal M, et al. 12 Weeks of daclatasvir in combination with sofosbuvir for HIV-HCV coinfection (ALLY-2 Study): efficacy and safety by HIV combination antiretroviral regimens. Clin Infect Dis. 2016;62(12):1489–1496.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, et al. Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world? Exp Rev Anti-Infective Ther. 2014;12:763–773.
   PubMed Web of Science ®Google Scholar
• Ravi S, Nasiri-Toosi M, Karimzadeh I, et al. Pattern and associated factors of anti-hepatitis C virus treatment-induced adverse reactions. Expert Opin Drug Saf. 2014;13(3):277–286.
   PubMed Web of Science ®Google Scholar
• Gentile I, Di Flumeri G, Scarica S. et al. Acute hepatitis C in patients undergoing hemodialysis: experience with high-dose interferon therapy. Minerva urologica e nefrologica Italian J urology and nephrol. 2013;65(1):83–84.
   PubMed Web of Science ®Google Scholar
• Borgia G, Maraolo AE, Buonomo AR, et al. The therapeutic potential of new investigational hepatitis C virus translation inhibitors. Expert Opin Invest Drugs. 2016;25(10):1209–1214.
   PubMed Web of Science ®Google Scholar
• Gentile I, Zappulo E, Buonomo AR, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111–1121.
   PubMed Web of Science ®Google Scholar
• Gentile I, Borgia F, Zappulo E, et al. Efficacy and safety of sofosbuvir in treatment of chronic hepatitis C: the dawn of a new era. Rev recent Clin trials. 2014;9:1-7.
   Google Scholar
• Tamai H, Shingaki N, Ida Y, et al. Real-world safety and efficacy of sofosbuvir and ledipasvir for elderly patients. JGH Open. 2018;2(6):300–306.
   PubMed Web of Science ®Google Scholar
• Gentile I, Scotto R, Zappulo E, et al. Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opin Investig Drugs. 2016;25(5):557–572.
   PubMed Web of Science ®Google Scholar
• Ahmed H, Abushouk AI, Menshawy A, et al. Safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin for treatment of hepatitis C virus genotype 1: a systematic review and meta-analysis. Clin Drug Investig. 2017;37(11):1009–1023.
   PubMed Web of Science ®Google Scholar
• Jafri S-M, Gordon SC. The safety of daclatasvir for the treatment of hepatitis C. Expert Opin Drug Saf. 2015;14(11):1787–1797.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther. 2014;12(9):1033–1043.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Coppola C, et al. Efficacy of the “first wave” Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort. New Microbiol. 2019; 41(2) :94-100.
   Google Scholar
• Coppola N, Portunato F, Buonomo AR, et al. Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. J nephrol. 2019;32(5):11.
   Web of Science ®Google Scholar
• Gentile I, Scotto R Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort). 2018.
   Google Scholar
• European Association for the Study of the Liver. Recommendations on Treatment of Hepatitis C 2018. [cited Sep 20]. Availablefrom: https://easl.eu/publication/easl-recommendations-treatment-of-hepatitis-c/
   Google Scholar
• Mohammed Abdul MK, Snyder HS, Chunduru M, et al. Hepatitis C virus in the elderly in the direct-acting antiviral era: from diagnosis to cure. Curr Treat Options Infect Dis. 2020; 1–14. DOI: https://doi.org/10.1007/s40506-020-00231-8.
   Google Scholar
• Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;1(Pt 1):15–20.
   Google Scholar
• Ramachandran J, Sajith KG, Priya S, et al. Serum cholinesterase is an excellent biomarker of liver cirrhosis. Trop Gastroenterol: official journal of the Digestive Disease Foundation. 2014;35(1):15–20.
   PubMedGoogle Scholar
• Procopet B, Berzigotti A. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol report. 2017;5(2):79–89.
   Google Scholar
• Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008;48(6):1000–1007.
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E. et al. Is it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters? Le infezioni in medicina: rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive. 2014;22(1):11–18.
   PubMedGoogle Scholar
• Nyblom H, Bjornsson E, Simren M, et al. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int: official journal of the International Association for the Study of the Liver. 2006;26(7):840–845.
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO. clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2012;2013(Suppl 3):1–150.
   Google Scholar
• World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Advocacy Brief. 2016. [cited Sep 2020]. Available at: http://apps.who.int/iris/bitstream/10665/206453/1/WHO_HIV_2016.04_eng.pdf?ua=1
   Google Scholar
• Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386(10003):1537–1545.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology. 2017;153(1):113–122.
   PubMed Web of Science ®Google Scholar
• Esteban R, Pineda JA, Calleja JL, et al. Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis. Gastroenterology. 2018;155(4):1120–1127.
   PubMed Web of Science ®Google Scholar
• Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir with velpatasvir in treatment-naive noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163(11):818–826.
   PubMed Web of Science ®Google Scholar
• Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062–1068.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–2607.
   PubMed Web of Science ®Google Scholar
• Scotto R, Buonomo AR, Moriello NS, et al. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection. Rev Recent Clin Trials. 2019;14(3):173–182.
   PubMed Web of Science ®Google Scholar
• Gentile I, Pinchera B, Viceconte G. et al. Hepatitis C screening in the emergency department of a large hospital in southern Italy: results of a pilot study. Le Infezioni Med. 2019;27(1):32–39.
   PubMedGoogle Scholar
• Buonomo AR, Scotto R, Pinchera B, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol. 2018;41(1):26–29.
   PubMed Web of Science ®Google Scholar
• Cecere A, Marotta F, Lucariello A, et al. High prevalence of hepatitis C virus infection in a southern Italian rural region. Clinical aspects and evidence of inapparent parenteral exposure. Panminerva Med. 2003;45(4):253–259.
   PubMed Web of Science ®Google Scholar
• Craxì L. HCV Eradication: a duty of the state, an option for the individual. Adv Exp Med Biol. 2019. DOI:https://doi.org/10.1007/5584_2019_452
   Google Scholar
• Villani R, Monami M, Di Cosimo F, et al. Direct-acting antivirals for HCV treatment in older patients: a systematic review and meta-analysis.Journal of Viral Hepatitis. 2018;155(4):1249–1256.
   Google Scholar
• Belperio PS, Shahoumian TA, Loomis TP, et al. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol. 2019;70(1):15–23.
   PubMed Web of Science ®Google Scholar
• Ahmed H, Abushouk AI, Attia A, et al. Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: a systematic review and meta-analysis. Journal of Infection and Public Health. 2018;41(1):156–164.
   Google Scholar
• D’Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):22.
   Web of Science ®Google Scholar